Vericel Corp
NASDAQ:VCEL

Watchlist Manager
Vericel Corp Logo
Vericel Corp
NASDAQ:VCEL
Watchlist
Price: 36.59 USD 0.14%
Market Cap: 1.9B USD

Relative Value

The Relative Value of one VCEL stock under the Base Case scenario is 38.36 USD. Compared to the current market price of 36.59 USD, Vericel Corp is Undervalued by 5%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VCEL Relative Value
Base Case
38.36 USD
Undervaluation 5%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
90
vs Industry
44
Median 3Y
9
Median 5Y
9.5
Industry
7.9
Forward
6.6
vs History
52
vs Industry
0
Median 3Y
144.5
Median 5Y
245.7
Industry
23.7
Forward
133.4
vs History
95
vs Industry
4
Median 3Y
51.8
Median 5Y
59.1
Industry
22
vs History
60
vs Industry
0
Median 3Y
93.7
Median 5Y
98.7
Industry
23.8
vs History
95
vs Industry
11
Median 3Y
7.9
Median 5Y
8.4
Industry
3.3
vs History
90
vs Industry
37
Median 3Y
8.5
Median 5Y
8.9
Industry
8.3
Forward
6.1
vs History
95
vs Industry
33
Median 3Y
12.5
Median 5Y
13.1
Industry
10.1
vs History
52
vs Industry
0
Median 3Y
103
Median 5Y
176.9
Industry
6.4
Forward
23.9
vs History
30
vs Industry
0
Median 3Y
-106.1
Median 5Y
-78.6
Industry
7
Forward
162
vs History
95
vs Industry
4
Median 3Y
48.8
Median 5Y
55.6
Industry
8.3
vs History
61
vs Industry
0
Median 3Y
86.1
Median 5Y
93.8
Industry
6.5
vs History
92
vs Industry
23
Median 3Y
8.3
Median 5Y
9.2
Industry
5.7

Multiples Across Competitors

VCEL Competitors Multiples
Vericel Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Vericel Corp
NASDAQ:VCEL
1.8B USD 7.1 141.4 100.6 241.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 809 907.8 -160 693.5 -195 133.1 -192 906.4
US
Abbvie Inc
NYSE:ABBV
400.7B USD 6.7 170.6 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
172.3B USD 4.8 24.6 17.8 17.8
US
Gilead Sciences Inc
NASDAQ:GILD
149.8B USD 5.1 18.5 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.6B USD 9.8 31.1 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 083.7 -531.7 -579 -563.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD 5.6 17.3 16.5 18.7
AU
CSL Ltd
ASX:CSL
86.8B AUD 3.7 19.2 12.9 16.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52B USD 16.2 1 194.7 156.9 190.3
NL
argenx SE
XBRU:ARGX
42.9B EUR 14 32.9 56.5 58.1
P/E Multiple
Earnings Growth PEG
US
Vericel Corp
NASDAQ:VCEL
Average P/E: 183.4
141.4
67%
2.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 693.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.6
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
9%
1.9
AU
CSL Ltd
ASX:CSL
19.2
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 194.7
N/A N/A
NL
argenx SE
XBRU:ARGX
32.9
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Vericel Corp
NASDAQ:VCEL
Average EV/EBITDA: 45.9
100.6
130%
0.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 133.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.8
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
12.9
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
156.9
N/A N/A
NL
argenx SE
XBRU:ARGX
56.5
839%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Vericel Corp
NASDAQ:VCEL
Average EV/EBIT: 66.9
241.2
136%
1.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 906.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.8
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
13%
1.4
AU
CSL Ltd
ASX:CSL
16.1
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
190.3
N/A N/A
NL
argenx SE
XBRU:ARGX
58.1
N/A N/A